---
title: "CICC Sticks to Their Buy Rating for Innovent Biologics (IVBXF)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285050005.md"
description: "CICC analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$118.30.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$118.15."
datetime: "2026-05-04T09:15:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285050005.md)
  - [en](https://longbridge.com/en/news/285050005.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285050005.md)
---

# CICC Sticks to Their Buy Rating for Innovent Biologics (IVBXF)

CICC analyst maintained a Buy rating on Innovent Biologics yesterday and set a price target of HK$118.30.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$118.15.

### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [03908.HK](https://longbridge.com/en/quote/03908.HK.md)
- [601995.CN](https://longbridge.com/en/quote/601995.CN.md)

## Related News & Research

- [Guotai Haitong Sticks to Its Buy Rating for China Oriental Group Co (CUGCF)](https://longbridge.com/en/news/284705186.md)
- [BOCOM International Holdings Company Keeps Their Buy Rating on Innovent Biologics (IVBXF)](https://longbridge.com/en/news/275707835.md)
- [Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD](https://longbridge.com/en/news/280236866.md)
- [Baader Bank Reaffirms Their Buy Rating on Fielmann (0MG1)](https://longbridge.com/en/news/284741478.md)
- [Barclays Reaffirms Their Buy Rating on Nemetschek (0FDT)](https://longbridge.com/en/news/284741802.md)